TICKERNERD
Menu
BOLTBOLTHealthcare · Biotechnology

BOLT Stock Forecast: Bolt Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$6.11
+3.38% on the day

The 3 Wall Street analysts covering Bolt Biotherapeutics, Inc. hold a median 12-month price target of $41 — +571.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 13 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$13.9M
Ticker Nerd rank
84/ 100
Median analyst target
$41
Analysts covering
3
Revenue$5K−99.7% y/y
Operating income−$7.6M
Net income−$7.7M
Free cash flow−$6.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.6%
1M
+42.6%
YTD
+11.7%
1Y
+30.0%
From 52W high
−13.8%
From 52W low
+92.3%
$3.18
$7.09
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BOLT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bolt Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Nov 2026
84/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
91
Issuance
90
Size
90
Accruals
75
Momentum
59
Quality
55
Growth
54
Value
52
Revisions
45

Volatility (91): The share price has been relatively steady.

Revisions (45): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BOLT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BOLT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$20.00$40.00$60.00$80.00Jan 26Apr 26Jul 26Oct 26BOLTHigh $75Median $41Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $7Median $41High $75

The green dot is the last close — the median target sits +571.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 May 2026Rodman & RenshawInitiatesBuy$22
28 May 2026HC Wainwright & Co.ReiteratesBuy$7.00
13 Mar 2026HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025HC Wainwright & Co.AssumesBuy$7.00
15 Aug 2025Lake StreetMaintainsBuy—
20 May 2025Lake StreetInitiatesBuy—
13 May 2025StifelMaintainsHold—
25 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
25 Mar 2025StifelMaintainsHold—
13 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
15 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
15 May 2024GuggenheimDowngradeNeutral—
15 May 2024HC Wainwright & Co.DowngradeNeutral—
15 May 2024Jones TradingDowngradeHold—
15 May 2024Leerink PartnersDowngradeMarket Perform—
15 May 2024StifelDowngradeHold—
22 Mar 2024HC Wainwright & Co.MaintainsBuy—
8 Aug 2023HC Wainwright & Co.ReiteratesBuy—
3 Aug 2023HC Wainwright & Co.ReiteratesBuy—
5 June 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BOLT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BOLT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, Bolt Biotherapeutics, Inc. returned +30.0% against +13.4% for the S&P 500, dividends included.

BOLT vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26BOLTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BOLT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Bolt Biotherapeutics, Inc. (BOLT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 80% of US stocks

Price / sales
1.8×

Cheaper than 53% of US stocks

Price / book
0.9×

Cheaper than 73% of US stocks

EV / EBITDA
−0.8×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
−80.8%

Higher than 3% of US stocks

Earnings growth (YoY)
−99.7%

Higher than 2% of US stocks

Gross margin
—
Operating margin
−450.1%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−125.9%

Higher than 11% of US stocks

Return on assets
−58.8%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bolt Biotherapeutics, Inc. (BOLT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bolt Biotherapeutics, Inc. has a market value of $13.9M and an enterprise value of $25.2M.

  • Revenue in the twelve months to 30 June 2026: $4.7M. The latest quarter shrank 80.8% year on year.

  • Net income over the same four quarters: −$28.7M, a −611.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$16.44.

  • Free cash flow in the twelve months to 30 June 2026: −$31.5M.

  • Shares outstanding: 1.9M.

  • Trailing P/E: −0.3×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Bolt Biotherapeutics, Inc. employs 52 people — $90K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Nov 2026

Data provided by Twelve Data

Peers

BOLT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BOLTBolt Biotherapeutics, Inc.$13.9M84
CLRBCellectar Biosciences, Inc.$11.4M23
GUTSFractyl Health, Inc.$12.0M31
PBMPsyence Biomedical Ltd.$12.0M4
BIVIBioVie, Inc.$12.1M29
PTNPalatin Technologies, Inc.$11.1M40
HINDVyome Holdings, Inc.$11.1M27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bolt Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BOLT news & analysis

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 12 Nov 2026positive

Bolt reported completing its acquisition of Prana Therapies and a concurrent $120 million private placement, making PRA-216 and the INSPIRE-built pipeline its primary development focus. The company has initiated Phase 2 studies of PRA-216 in asthma, atopic dermatitis and COPD, and expects initial data in the second quarter of 2027.

Why it matters — The acquisition, financing and clinical milestones outline Bolt’s development priorities and its stated cash runway into 2028.

Bolt Biotherapeutics to Participate in Upcoming Conferences

GlobeNewsWire · 3 Nov 2026neutral

Bolt Biotherapeutics announced that it will participate in two upcoming investor conferences.

Why it matters — The announcement gives BOLT watchers notice of upcoming opportunities to hear from the company.

Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript

Seeking Alpha · 26 Oct 2026neutral

The source identifies a Seeking Alpha transcript of Bolt Biotherapeutics’ M&A call prepared remarks, but provides no details about the remarks or transaction.

Why it matters — BOLT watchers may note the existence of an M&A call transcript, though the excerpt does not provide information about its contents.

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications

GlobeNewsWire · 23 Oct 2026positive

Bolt Biotherapeutics announced its acquisition of clinical-stage company Prana Therapies and a concurrent $120 million private placement. Bolt said it will focus on advancing Prana’s INSPIRE-platform antibody pipeline, led by PRA-216, which is in Phase 2 development for asthma, COPD and atopic dermatitis; a Phase 2 EoE study is planned.

Why it matters — The acquisition and financing mark a shift in Bolt’s focus toward Prana’s multispecific antibody pipeline and support the development of PRA-216 across several inflammatory indications.

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 11 Aug 2026negative

Bolt Biotherapeutics reported a quarterly loss of $4.57 per share, wider than the Zacks Consensus Estimate of a $2.97 loss and slightly larger than the $4.46 per share loss a year ago. The company also missed revenue estimates for the quarter.

Why it matters — BOLT watchers would care because the quarterly loss came in well above consensus expectations while revenue fell short of estimates, signalling weaker-than-anticipated performance.

FAQ

Frequently asked questions about BOLT stock

What is the BOLT stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Bolt Biotherapeutics, Inc. have a median 12-month price target of $41, with estimates ranging from $7 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BOLT stock a buy right now?

Of the 3 analysts covering Bolt Biotherapeutics, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bolt Biotherapeutics, Inc. 84 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BOLT?

As at 13 Nov 2026, Bolt Biotherapeutics, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (91 of 100).

Will BOLT stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +571.0% from the last close, and Ticker Nerd's factor model ranks Bolt Biotherapeutics, Inc. 84 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BOLT stock forecast for 2030?

No analyst covering Bolt Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BOLT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $75 over the next 12 months.

How has BOLT stock performed over the past year?

Bolt Biotherapeutics, Inc. returned +30.0% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bolt Biotherapeutics, Inc. do?

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer.

What is the latest news on BOLT?

The most recent item we track (GlobeNewsWire, 12 Nov 2026): "Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update". Bolt reported completing its acquisition of Prana Therapies and a concurrent $120 million private placement, making PRA-216 and the INSPIRE-built pipeline its primary development focus. The company has initiated Phase 2 studies of PRA-216 in asthma, atopic dermatitis and COPD, and expects initial data in the second quarter of 2027.

Company

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. The company’s current programs center on novel approaches that engage the immune system, including its Boltbody Immune-Stimulating Antibody Conjugate platform and myeloid-directed antibodies designed to activate tumor-fighting immune responses. Its pipeline includes candidates that target specific cancer markers and tumor biology, reflecting a focus on precision immuno-oncology rather than broad, traditional chemotherapy. Bolt Biotherapeutics works within the biotechnology and cancer treatment markets, where it contributes to the development of targeted therapies intended to address unmet needs in oncology. Based in Redwood City, California, the company operates as a public biotech enterprise with a research and development model centered on advancing experimental cancer treatments through clinical evaluation.

CEO Mr. William P. Quinn · 52 employees · United States · https://www.boltbio.com